A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma.
about
Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects.Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.Skin concentrations and pharmacokinetics of posaconazole after oral administration.A Comparative Study of Newly Developed HPLC-DAD and UHPLC-UV Assays for the Determination of Posaconazole in Bulk Powder and Suspension Dosage Form.Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia.Ultra-performance liquid chromatography mass spectrometry and sensitive bioassay methods for quantification of posaconazole plasma concentrations after oral dosing.Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, andAdvances in ultrasensitive mass spectrometry of organic molecules.Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity.Pharmacokinetics and safety study of posaconazole intravenous solution administered peripherally to healthy subjects.Determination of posaconazole levels in toenails of adults with onychomycosis following oral treatment with four regimens of posaconazole for 12 or 24 weeksDetection of posaconazole by surface-assisted laser desorption/ionization mass spectrometry with dispersive liquid-liquid microextraction.Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation.Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection.Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension.A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers.High Performance Liquid Chromatographic Assay for the Simultaneous Determination of Posaconazole and Vincristine in Rat Plasma.Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteersEffect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers.Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma.Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.Stability-indicating HPLC method for posaconazole bulk assay.Impact of glucuronide interferences on therapeutic drug monitoring of posaconazole by tandem mass spectrometry.Liquid chromatography-tandem mass spectrometry method for simultaneous quantification of four triazole antifungal agents in human plasma.A routine method for the quantification of the novel antimycotic drug posaconazole in plasma using liquid chromatography-tandem mass spectrometry.Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers.
P2860
Q33798286-BAA7EAC5-0C44-4D2F-B809-2A28438D51ACQ33798313-22C96942-16C2-4167-AF4F-C86FE5699230Q33826421-3ED19E51-DC4A-45CF-B466-B6CEE3500372Q34203436-DD491C2C-CFBE-4F3F-9A9B-5603975495D4Q34299092-C14273D1-65B5-4407-869D-A2716694D42DQ34309527-08B45274-EC07-474F-97DA-3FF5E60224CEQ34309603-8F955C23-816C-4B11-8F41-4CF465263447Q34331730-E4905CA9-AD08-432A-819B-D6F29397E022Q34596950-716059F4-3AB5-4FE0-9758-F37CC8E0DAD7Q35105840-AFB81475-2D73-42E9-A58C-F476216EE964Q35191482-89D0E462-55F8-4C12-B5DB-D89F20F2D090Q35538500-6508EA1C-CAF5-464A-A7E8-A8857CEFA6A8Q35607672-0C9D9AA7-FA07-4D1F-ABC0-7CE3570B4093Q35941414-D5302766-24F9-42F9-9EC6-491CB4940386Q36018743-17158323-697B-4BC3-AE9A-D3AAE67D74D2Q36171677-81B3A31C-CC1A-460C-B65A-840CD83F4FF5Q36308059-C20DF47B-B9C9-460B-993B-5D8A474D1FB6Q36726855-639004F3-1239-460F-8A21-50A0867D04BBQ37072036-A6BE396C-7BEA-49C0-9380-1988275753F1Q37115829-37F992CC-D17C-4589-A4D7-EA7933AB1368Q37247780-5B967FE5-22A1-493F-9F0C-337BC2979F98Q37409875-B20C41BA-5DF1-4960-A66F-26A57B79E7FEQ40892430-7CC8A0B1-C2FC-431B-B96F-257F3D769A8EQ41916356-A13AA21B-E84A-44D8-A620-4BD08CD3C879Q41993016-ADE17B38-C57D-49F2-809B-455D55F7622FQ42091704-FE52FF05-90EB-411C-A561-A9C1B91705ECQ42939581-9DA21D2A-C3EC-40C3-818D-CA7293F48D34Q43015024-179316E1-D7B6-4519-AECD-9734E3A43D98Q45172325-44758049-404C-42BA-B802-63E5295B4401Q46341880-78D17EE1-3AA2-4AAA-A11C-E33FC30B7A16Q48202863-1C9C94C5-7FC0-44F3-8CB5-251563BC3A52
P2860
A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
A sensitive liquid chromatogra ...... posaconazole in human plasma.
@ast
A sensitive liquid chromatogra ...... posaconazole in human plasma.
@en
type
label
A sensitive liquid chromatogra ...... posaconazole in human plasma.
@ast
A sensitive liquid chromatogra ...... posaconazole in human plasma.
@en
prefLabel
A sensitive liquid chromatogra ...... posaconazole in human plasma.
@ast
A sensitive liquid chromatogra ...... posaconazole in human plasma.
@en
P1476
A sensitive liquid chromatogra ...... posaconazole in human plasma.
@en
P2093
Gopal Krishna
Roger N Hayes
P304
P356
10.1016/J.JPBA.2006.06.011
P50
P577
2006-07-21T00:00:00Z